The present study was intended to provide proof-of-principle data regarding the feasibility of a targeted intervention to prevent CTx-induced endothelial dysfunction ex vivo, and it is crucial to note that the effect of VEGF-B manipulation on in vivo microvascular function, tumor growth, or CTx efficacy is currently unknown in humans. This evidence concerns the gene VEGFB and endothelial dysfunction.